Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 11/20 | 0.47 |
| ▸ | CALCR | P30988 | 11/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593253 | 0.86 | APLNR (0.50) | RAMP3CALCRAPLNR | |
| SCHEMBL31468806 | 0.86 | APLNR (0.44) | APLNR | |
| SCHEMBL31593245 | 0.85 | OPRL1 (0.48) | RAMP3CALCR | |
| SCHEMBL31593304 | 0.85 | APLNR (0.47) | APLNRCXCR4 | |
| SCHEMBL30033898 | 0.85 | TFPI (0.51) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30542978 | 0.85 | TFPI (0.51) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31593286 | 0.84 | IL23R (0.46) | IL23R | |
| SCHEMBL30542980 | 0.84 | CXCR4 (0.49) | RAMP3CALCRAPLNRCXCR4NPY2R | |
| SCHEMBL30033879 | 0.84 | CXCR4 (0.49) | RAMP3CALCRAPLNRCXCR4NPY2R | |
| SCHEMBL31119609 | 0.84 | APLNR (0.55) | APLNRIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | RAMP3 3434/4885CALCR 3230/4885APLNR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.